FOLFIRI-bevacizumab As a Second-line Treatment for Advanced Biliary Tract Cancer After Gemcitabine-based Chemotherapy

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Dec 15

PMID 38098503

Authors

Nicolas Roussot

Julie Vincent

Remi Palmier

Guillaume Constantin

Leila Bengrine

Jean-David Fumet

Francois Ghiringhelli

Affiliations

Soon will be listed here.

Abstract

Background: Advanced biliary tract cancer (BTC) has a poor prognosis. Gemcitabine with platinum chemotherapy was the standard first-line chemotherapeutic regimen until the recent addition of anti-PD-1/PD-L1 antibodies. After disease progression, the only second-line chemotherapy that has demonstrated a survival benefit versus supportive care is FOLFOX (folinic acid, fluorouracil, and oxaliplatin), with a modest benefit. This study aimed to assess the efficacy and safety of second-line FOLFIRI (folinic acid, fluorouracil, and irinotecan) combined with bevacizumab for advanced BTC.

Methods: This single-center retrospective study enrolled patients with metastatic BTC (intrahepatic cholangiocarcinoma [ICC], extrahepatic cholangiocarcinoma [ECC], or gallbladder carcinoma) that progressed after first-line gemcitabine-based chemotherapy. FOLFIRI-bevacizumab was administered intravenously every 2 weeks [folinic acid 200 mg/m², fluorouracil 400 mg/m² (bolus), fluorouracil 2400 mg/m² (46-h continuous intravenous infusion), irinotecan 180 mg/m², and bevacizumab 5 mg/kg] until unacceptable toxicity, patient refusal, or disease progression.

Results: Overall, 28 patients received the FOLFIRI-bevacizumab regimen after gemcitabine-based chemotherapy. The median overall survival (OS) was 9.0 months (95% CI 6.4-16.5). The OS rate was 39.3% (95% CI 24.8-62.3) and 10.7% (95% CI 3.7-32.1) at 12- and 24-months respectively. The median progression-free survival (PFS) was 5.2 months (95% CI 3.1-10.2) with FOLFIRI-bevacizumab. The PFS rates at 12 months and 24 months were 17.9% (95% CI 8.19-39.5] and 10.7% (95% CI 3.7-31.2), respectively. The overall response rate (ORR) to FOLFIRI-bevacizumab was 23.1%, with a disease control rate (DCR) of 69.3%. Grade 3-4 adverse events (sAE) were reported in 20 patients (71.4%) treated with FOLFIRI-bevacizumab.

Conclusion: FOLFIRI-bevacizumab as a second-line treatment for advanced BTC after gemcitabine-based chemotherapy showed efficacy and safety with a promising tumor response rate in this retrospective single-center study.

References

Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M . Genomic spectra of biliary tract cancer. Nat Genet. 2015; 47(9):1003-10. DOI: 10.1038/ng.3375. View

Abou-Alfa G, Macarulla T, Javle M, Kelley R, Lubner S, Adeva J . Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020; 21(6):796-807. PMC: 7523268. DOI: 10.1016/S1470-2045(20)30157-1. View

Marabelle A, Le D, Ascierto P, Di Giacomo A, De Jesus-Acosta A, Delord J . Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2019; 38(1):1-10. PMC: 8184060. DOI: 10.1200/JCO.19.02105. View

Jusakul A, Cutcutache I, Yong C, Lim J, Huang M, Padmanabhan N . Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. Cancer Discov. 2017; 7(10):1116-1135. PMC: 5628134. DOI: 10.1158/2159-8290.CD-17-0368. View

Lee C, Chon H, Cheon J, Lee M, Im H, Jang J . Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14). Lancet Gastroenterol Hepatol. 2022; 8(1):56-65. DOI: 10.1016/S2468-1253(22)00335-1. View

Ioka T, Kanai M, Kobayashi S, Sakai D, Eguchi H, Baba H . Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA). J Hepatobiliary Pancreat Sci. 2022; 30(1):102-110. PMC: 10086809. DOI: 10.1002/jhbp.1219. View

Jang J, Lim H, Hwang I, Song H, Yoo N, Yoon S . Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial. Cancer Chemother Pharmacol. 2009; 65(4):641-7. DOI: 10.1007/s00280-009-1069-7. View

Yoo C, Kim K, Jeong J, Kim I, Kang M, Cheon J . Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. Lancet Oncol. 2021; 22(11):1560-1572. DOI: 10.1016/S1470-2045(21)00486-1. View

Valle J, Vogel A, Denlinger C, He A, Bai L, Orlova R . Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study. Lancet Oncol. 2021; 22(10):1468-1482. DOI: 10.1016/S1470-2045(21)00409-5. View

10.

Javle M, Lowery M, Shroff R, Weiss K, Springfeld C, Borad M . Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol. 2017; 36(3):276-282. PMC: 6075847. DOI: 10.1200/JCO.2017.75.5009. View

11.

Harder J, Riecken B, Kummer O, Lohrmann C, Otto F, Usadel H . Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer. 2006; 95(7):848-52. PMC: 2360533. DOI: 10.1038/sj.bjc.6603334. View

12.

Mazzaferro V, Gorgen A, Roayaie S, Droz Dit Busset M, Sapisochin G . Liver resection and transplantation for intrahepatic cholangiocarcinoma. J Hepatol. 2020; 72(2):364-377. DOI: 10.1016/j.jhep.2019.11.020. View

13.

Fiteni F, Jary M, Monnien F, Nguyen T, Beohou E, Demarchi M . Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy. BMC Gastroenterol. 2014; 14:143. PMC: 4236575. DOI: 10.1186/1471-230X-14-143. View

14.

Vogel A, Bridgewater J, Edeline J, Kelley R, Klumpen H, Malka D . Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022; 34(2):127-140. DOI: 10.1016/j.annonc.2022.10.506. View

15.

Belkouz A, de Vos-Geelen J, Mathot R, Eskens F, van Gulik T, van Oijen M . Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial. Br J Cancer. 2020; 122(5):634-639. PMC: 7054309. DOI: 10.1038/s41416-019-0698-9. View

16.

Valle J, Borbath I, Khan S, Huguet F, Gruenberger T, Arnold D . Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016; 27(suppl 5):v28-v37. DOI: 10.1093/annonc/mdw324. View

17.

Guion-Dusserre J, Lorgis V, Vincent J, Bengrine L, Ghiringhelli F . FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma. World J Gastroenterol. 2015; 21(7):2096-101. PMC: 4326145. DOI: 10.3748/wjg.v21.i7.2096. View

18.

Bekaii-Saab T, Yaeger R, Spira A, Pelster M, Sabari J, Hafez N . Adagrasib in Advanced Solid Tumors Harboring a Mutation. J Clin Oncol. 2023; 41(25):4097-4106. PMC: 10852394. DOI: 10.1200/JCO.23.00434. View

19.

Huang P, Huang X, Zhou Y, Yang G, Sun Q, Shi G . The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Based on FOLFIRI for Advanced Intrahepatic Cholangiocarcinoma as Second-Line and Successive Treatment: A Real-World Study. Can J Gastroenterol Hepatol. 2022; 2022:9680933. PMC: 9529477. DOI: 10.1155/2022/9680933. View

20.

Verlingue L, Malka D, Allorant A, Massard C, Ferte C, Lacroix L . Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial. Eur J Cancer. 2017; 87:122-130. DOI: 10.1016/j.ejca.2017.10.013. View